Liver Enzymes In Patients with Chronic Kidney Diseases Undergoing Hemodialysis

Authors

  • Dr. Tera Aruna Kumari
  • Dr. Sonali S. Bhagat
  • Dr. P. V. Satyanarayana

Keywords:

Chronic Kidney Disease (CKD), Aspartate Transaminase (AST), Alanine Transaminase (ALT), Liver enzyme

Abstract

Chronic Kidney Diseases (CKD) is a worldwide public health problem. Chronic renal failure patients requires treatment with dialysis or transplantation is the most visible outcome of CKD. The present study was aimed to determine the aspartate transaminase (AST) and alanine transaminase (ALT) levels with baseline parameters in patients with chronic kidney diseases. Total 85 patients were studied in between age group 40 to 70 years. After applying the inclusion and exclusion criteria, a total of 50 chronic kidney disease patients were eligible for the study. The data was collected and compared with 50 age and sex matched healthy controls from the same age group. The statistical analysis was done using SPSS 16.0 software. All the patients were assessed with baseline parameters like RBS (Random Blood Sugar), blood urea, creatinine, total cholesterol and liver enzymes such as AST and ALT. the concentrations of RBS, blood urea, creatinine total cholesterol and were significantly elevated (P<0.001) and AST along with ALT were significantly declined when compared with control group. The serum transaminase levels were declined significantly in patients with kidney diseases on hemodialysis than normal renal function patients. It has a multifactorial origin.

Downloads

Download data is not yet available.

References

Mark J. Sarnak, Cochair Andrew S. Levey, Cochair. Anton C. Schoolwerth, Cochair et al. Kidney Disease as a Risk Factor for Development of cardiovascular disease. Circulation 2003;108:2154-2169.

National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. US Renal Data System, USRDS 2000 Annual Data Report. Bethesda. Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2000.Available

Shulman NB, Ford CE, Hall WD, et al Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: results from the hypertension detection and follow-up program The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension. 1989:13(5suppl):180-193.

Bogarapu Kiranmayi., A. Navaneetha Lakshmi, R.Tagore. Chandrakala Kambar. Evaluation of Cardiac Markers in Chronic Renal Failure. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)2015;14(1):46-52.

Luis Henrique Bezerra Cavalcanti Sette. Edmundo Pessoa De Almeida Lopes. Liver enzyrmes serum levels in patients with chronic kidney diseases on hemodialysis: a comprehensive review, Clinics 2014:69(4):217-278.

Kim YJ, Jang BK, Kim ES, Park KS, Cho KB Chung WJ, et al. Rapid normalization of alanine aminotransferase predicts viral response during combined peginterferon and ribavirin treatment in chronic hepatitis patents. Korean Hepato 2012;18(1):41-7.

Fabrizi F, Poordad FF, Martin P Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 2002,36(1):3-10.

Trinder, P et al., Determination of glucose in blood using glucose oxidase with an altrernative oxygen acceptar; Ann. Clin.Chem. 6(24) 1969.

Fawsett J K, and J E Seoh, A Rapid and precise method for determination of urea; Journal of Clin Path. 13, 156-159; 1960.

Bonsnes R W, Taussky H A,; On the Colorimetric termination of creatinine by the Jaffe’s reaction. Journal of Biological Chemistry, 158,581,1945.

Allain C.C., Poon L.S., Chan C.S.G., Richmond W. and Fu et al, Enzymatic Determination of Total Serum Cholesterol, Clin. Chem., 20(470) 1974.

Carl A Burtis, Edward R Ashwood, Fundamentals of clinical chemistry 5th edition, Norbert W. Teitz, WB Sanders Company.

Bradely DW, Maynard JE, Emery G and Webster H. Clin Chem, 18;1442 (1972).

Cinica Chemica Acta, (105,145-175F), 1980.

Ono K, Ono T, Matsumata T. The pathogenesis of decreased aspartate aminotransferase and alanine aminotransferase activity in the plasma of hemdialysis patients the role of vitamin B6 deficiency. Clin Nephrol. 1998;43(6):405-8.

Crawford DR, Reyna RS, Weiner MW. Effects of in vivo and vitro in dialysis on plasma transaminase activity. Nephron. 1978;22(4-6):418-22.

Rahul A Nathwani, Shireen Pais, Telfer B Reynolds, Neil Kaplowitz Serum alanine transaminase in skeletal muscle diseases. Hepatology 2005;41(2):380.382.

Downloads

Published

2017-03-15

How to Cite

Dr. Tera Aruna Kumari, Bhagat, D. S. S. . . . . . . . . . . . . . . . . . . . . . . . . . . ., & Dr. P. V. Satyanarayana. (2017). Liver Enzymes In Patients with Chronic Kidney Diseases Undergoing Hemodialysis. VIMS Health Science Journal, 4(1), 7–9. Retrieved from https://vimshsj.edu.in/index.php/main/article/view/113

Issue

Section

Articles

Most read articles by the same author(s)